Why are prescription drugs are often priced lower overseas? Many countries perform detailed assessments of the economic value of drugs and their benefits, and this could work in the U.S., says William Padula
Goldman, Van Nuys and colleagues propose a three-part pricing (TPP) model that ties prices to value but removes the need to monitor efficacy in each patient. The model creates a tiered system, with prices varying over fixed time intervals.
On October 26, U.S. Secretary of Health and Human Services Alex Azar visited Brookings to deliver remarks on a top administration priority. After delivering his prepared remarks he sat down for a discussion with Paul Ginsburg.